Peptide 101: MK-677 (Ibutamoren)
MK-677 is a once-a-day pill that tells your body to make more of its own growth hormone, which then raises a related hormone called IGF-1. It is not a peptide; it is a man-made small molecule, and despite how it is marketed online, it has never been approved by the FDA and is not a supplement. In studies it increased lean body mass and improved some sleep measures, but those lean-mass gains did not make people meaningfully stronger, and a trial in Alzheimer patients showed it raised IGF-1 without helping symptoms. The main downsides are a bigger appetite, water retention and puffiness, higher blood sugar with reduced insulin sensitivity, and a heart-failure safety signal seen in a study of frail elderly patients. If you are considering it, the most important conversations with a clinician are about your blood sugar, your heart, and the fact that what you can buy is unregulated.
How it works
Think of your growth-hormone system like a thermostat that naturally turns down as you age. Injectable growth hormone is like jamming the heat on manually, overriding the body's own controls. MK-677 instead nudges the thermostat's dial back up, so your own system releases growth hormone in its normal rhythm. The catch is that turning that dial also opens a few other vents you did not ask for, namely a bigger appetite, some water retention, and a tendency for blood sugar to trend upward.
MK-677 is a non-peptide agonist of the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by the natural hormone ghrelin. Binding this receptor in the anterior pituitary and hypothalamus amplifies the body's own pulsatile secretion of growth hormone, which then drives hepatic and peripheral production of IGF-1 and IGF-binding protein 3 (IGFBP-3). Because it stimulates the body's endogenous GH axis rather than supplying GH directly, it preserves the natural pulsatile pattern of GH release. As an orally bioavailable small molecule, it does not require injection. Activation of the ghrelin pathway also explains its characteristic non-GH effects: increased appetite, and modest rises in cortisol. Reported metabolic trade-offs include fluid retention and decreased insulin sensitivity with elevated fasting glucose.
What the evidence shows
Overall strength of the evidence, by our read: Emerging. Some of what that rests on:
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial (2008) — In a 2-year double-blind, placebo-controlled trial of 65 healthy adults aged 60-81, oral MK-677 25 mg daily raised growth hormone and IGF-1 into the young-adult range and was associated with an increase in fat-free mass (+1.1 kg vs -0.5 kg with placebo over 12 months; P<0.001). Fasting glucose rose by about 5 mg/dL and insulin sensitivity decreased; the increase in fat-free mass did not translate into measurable gains in strength or physical function.
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (1998) — In a double-blind, placebo-controlled crossover study of 8 healthy calorically restricted volunteers, oral MK-677 25 mg daily was associated with a shift toward positive nitrogen balance (+0.31 vs -1.48 g/day with placebo; P<0.01) and higher IGF-1 over a 7-day treatment period.
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man (1997) — In small double-blind crossover studies in young and older adults, oral MK-677 was associated with increases in stage IV (deep) and REM sleep and fewer deviations from normal sleep architecture compared with placebo.
Note, preliminary or early findings are not the same as proof. Any use beyond a peptide's FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.
Safety
The most commonly reported effects in clinical trials were increased appetite (which often subsided after a few months), transient mild swelling of the lower legs (edema), and muscle pain. Metabolically, MK-677 raised fasting blood glucose and reduced insulin sensitivity, which is a meaningful concern for anyone with prediabetes or diabetes. It modestly increased cortisol levels and produced changes in bone-turnover markers. Fluid retention can cause weight gain, puffiness, and joint discomfort. A phase IIb trial in elderly hip-fracture patients was terminated early after a safety signal of congestive heart failure in a small number of participants, so cardiac risk, particularly in older or fluid-overloaded individuals, is a notable caution. Because product sold online is unregulated, additional risks from impurities, mislabeling, or incorrect dosing apply.
Reasons to avoid it, or to talk to a clinician first:
Pregnancy, attempting conception, or breastfeeding (no safety data; raises IGF-1)
Diabetes, prediabetes, or significant insulin resistance, given reduced insulin sensitivity and higher fasting glucose
Heart failure or significant cardiac disease, given fluid retention and an observed congestive-heart-failure safety signal
Active or history of cancer, or high cancer risk, because of theoretical concern with elevating IGF-1 (a growth-promoting factor)
Active acromegaly or known GH/IGF-1 excess
This is not a complete safety list. It is the set of things worth knowing before a conversation with a prescriber.
Questions worth bringing to a clinician
Given that MK-677 is not FDA-approved and is sold only as a research chemical, is there any role for it in my situation, and what are the safety and sourcing risks?
I have (or am at risk for) prediabetes, diabetes, or heart failure. How would raising my IGF-1 and lowering my insulin sensitivity affect those conditions?
What baseline and follow-up labs, including fasting glucose, HbA1c, and IGF-1, should I have if I were to consider this, and how often?
New research, translated
A Phase IIIb, Open-label, Pragmatic Study Evaluating Initiation Strategies for Survodutide, Including de Novo Use and Switching From Semaglutide or Tirzepatide, in Participants With Overweight/Obesity Without Diabetes Mellitus-SYNCHRONIZE® - START
2026-11-07 · INTERVENTIONAL · survodutide
Survodutide is an experimental weight-loss shot, in the same general family as Ozempic and Zepbound. Most trials ask whether a drug works; this one takes that for granted and asks how you actually start someone on it. Some people will be new to these drugs, and others will switch straight over from semaglutide or tirzepatide — that second group is the part worth watching, because doctors already move patients between these shots all the time with almost no research telling them how to do it. There is no placebo and no secrecy about who gets what, which makes the study look more like real life and makes the results easier to argue with. To join participates need a BMI of 30 or higher (or 27 with a weight-related health problem), no diabetes, and at least one past diet that did not work.
A Study of Real-World Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) in Bangladesh
2026-11 · OBSERVATIONAL · tirzepatide
Doctors across several clinics in Bangladesh are tracking adults with obesity who take tirzepatide (sold here as Mounjaro and Zepbound) and comparing them against people doing a structured diet and exercise program instead. That is worth doing, because nearly everything known about this drug comes from studies in North America and Europe, and South Asian patients tend to develop weight-related health problems at lower body weights. The catch is in how the study is built: nobody was assigned to a group by chance. People who can get tirzepatide in Bangladesh likely differ from people doing diet and exercise alone in ways that have more to do with money and access than with the drug. Read it as a snapshot of what is happening in real clinics, not as a fair contest between a shot and lifestyle change.
Lilly’s Brenipatide Shows Clinical Promise in Substance, Psych Disorders
Brenipatide is an experimental Eli Lilly injection aimed at the brain rather than the waistline, now in testing for alcohol addiction, depression, smoking relapse and several other conditions. The headline says clinical promise; what Lilly actually released was a first-round safety study in about 200 people — the kind that checks whether a drug is tolerable and how long it lingers in the body, not whether it helps anyone. The results were reassuring as far as they go: no deaths, no serious problems, and stomach side effects no more common than in people who got a placebo (a dummy injection). One thing did stand out — about 15 in every 100 people on the drug reported strange burning or tingling in the skin, and nobody on placebo did. Nothing here says brenipatide treats addiction or depression, and Lilly skipped the usual middle round of testing to go straight to the final large trials.
What readers are asking
Topics we'll be tracking:
Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide
Benzodiazepine Receptor Antagonism: Mechanistic Roles of Flumazenil and BPC-157 in Reversing Benzodiazepine Tolerance
About MK-677
MK-677 has NOT been evaluated or approved by the U.S. Food and Drug Administration for any medical use. It is not an FDA-approved drug, and its sale for human use may violate federal law under FD&C Act § 505(a). Any research discussed is for educational purposes only.
Medical disclaimer
This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.